Overall survival (OS) improved among patients with metastatic castration-sensitive prostate cancer (mCSPC) after the introduction of docetaxel and novel hormonal therapies (NHT; abiraterone, enzalutamide, apalutamide) for treating this disease state, according to study findings presented at ESMO Congress 2022.

Daniel J. George, MD, of Duke University Medical Center in Durham, North Carolina, and colleagues studied 39,292 patients with mCSPC (33,641 with Medicare coverage and 5651 receiving care at Veterans Affairs [VA] medical facilities).

The investigators divided patients into 3 cohorts who received first-line treatment for mCSPC:
• Those treated during 2010-2011, prior to the introduction of NHT for metastatic castration-resistant prostate cancer
• Those treated during 2012-2014, to reflect the introduction of NHT for metastatic castration-resistant prostate cancer
• Those treated during 2015-2018 (for Medicare patients) and 2015-2019 (for VA patients) to capture the effects of the introduction of NHT and docetaxel for treating mCSPC.


Continue Reading

Compared with Medicare and VA patients treated during 2010-2011, Medicare patients treated during 2015-2018 and VA patients treated during 2015-2019 had a significant 12% and 15% lower risk for death, respectively. OS did not improve during 2012-2014 compared with 2010-2011.

Although treatment intensification with NHT or doctaxel for mCSPC is standard of care, the investigators found that, as of 2018-2019, less than one-third of men with mCSPC received this regimen as first-line therapy.

“The underutilization of these agents in mCSPC suggests that further OS improvements may be possible,” the authors concluded.

Disclosures: The study was funded by Pfizer and Astellas Pharma. Some study authors declared affiliations with biotech, pharmaceutical, and/or device companies. Please see the original reference for a full list of disclosures.

Reference

George DJ, Sandin R, Agarwal N, et al. Treatment patterns and overall survival (OS) in metastatic castration-sensitive prostate cancer (mCSPC) from 2010 to 2019. Presented at ESMO 2022, September 9-13. Abstract 1384P.

This article originally appeared on Renal and Urology News